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Objectives The purpose of this study was to examine the role of heparanase in controlling thrombosis following vascular
injury or endovascular stenting.
Background The use of endovascular stents are a common clinical intervention for the treatment of arteries occluded due to
vascular disease. Both heparin and heparan sulfate are known to be potent inhibitors of thrombosis. Hepara-
nase is the major enzyme that degrades heparan sulfate in mammalian cells. This study examined the role of
heparanase in controlling thrombosis following vascular injury and stent-induced flow disturbance.
Methods This study used mice overexpressing human heparanase and examined the time to thrombosis using a laser-
induced arterial thrombosis model in combination with vascular injury. An ex vivo system was used to examine
the formation of thrombus to stent-induced flow disturbance.
Results In the absence of vascular injury, wild type and heparanase overexpressing (HPA Tg) mice had similar times to
thrombosis in a laser-induced arterial thrombosis model. However, in the presence of vascular injury, the time to
thrombosis was dramatically reduced in HPA Tg mice. An ex vivo system was used to flow blood from wild type
and HPA Tg mice over stents and stented arterial segments from both animal types. These studies demonstrate
markedly increased thromboses on stents with blood isolated from HPA Tg mice in comparison to blood from
wild type animals. We found that blood from HPA Tg animals had markedly increased thrombosis when applied
to stented arterial segments from either wild type or HPA Tg mice.
Conclusions Taken together, this study’s results indicate that heparanase is a powerful mediator of thrombosis in the context
of vascular injury and stent-induced flow disturbance. (J Am Coll Cardiol 2012;59:1551–60) © 2012 by the
American College of Cardiology Foundation
Published by Elsevier Inc. doi:10.1016/j.jacc.2011.11.057a
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iEndovascular stenting is a common clinical treatment for
arteries with occlusive disease due to atherosclerosis.
Whereas this treatment immediately increases blood flow to
the ischemic tissue, the vascular injury and indwelling stent
material can lead to restenosis of the artery through the
development of neointimal hyperplasia. Drug-eluting stent
technology has allowed the delivery of therapeutic agents to
inhibit the proliferation of vascular cells following stent
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2011, accepted November 11, 2011.implantation. Although these therapeutics have reduced the
incidence of restenosis (1), it has recently become evident
that these drugs also inhibit the normal healing of the
artery, and this has raised concerns of a prolonged risk of
thrombosis in drug-eluting stents (2). The placement of an
endovascular stent presents several major stimuli for the
formation of thrombosis, including endothelial injury, arte-
rial stretch with deep vascular injury, and locally disturbed
blood flow due to the indwelling stent. In this study, we
examined the role of heparanase in altering the thrombotic
potential of vascular injury and local stent-induced flow
disturbance.
Heparanase is a -endoglucuronidase that is the major
nd likely single mammalian enzyme that digests heparan
ulfate (3). Heparan sulfate is a glycosaminoglycan that is
ormed of long, linear repeating disaccharides that have
een altered by enzymes in the trans-Golgi to have an
ntricate pattern of sulfation, epimerization, and acetylation
4). Heparan sulfate’s anticoagulatory properties arise from
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with antithrombin III, an inhib-
itor of coagulation pathway en-
zymes, including thrombin and
factor Xa (5). This interaction is
analogous to the mechanism of
action of heparin (a highly sulfated
analogue of heparan sulfate) and re-
quires a highly sulfated pentasac-
charide sequence in the polysac-
charide chain (6). Recent studies
have identified that multiple clin-
ical disorders lead to the excessive
production of heparanase. Diabetes and vascular injury have
both been found to enhance arterial heparanase expression
(7,8). Heparanase itself is increased during neointimal hyper-
plasia, a process that can be greatly enhanced in the presence
of type II diabetes (8). In addition, heparanase expression is
elevated in many types of cancers and is critical to the
process of metastasis of several cancer types (9). Inflamma-
tion also increases both the local and systemic levels of
heparanase (10,11). Thus, heparanase overexpression has
the potential for mediating disease-induced changes in the
thrombotic potential of endovascular stents. Here, we ex-
amined the consequences of heparanase overexpression on
the thrombotic response to vascular injury and stent-
induced flow disturbance. We show that heparanase over-
expression does not increase thrombosis in the case of
simple endothelial injury but has a profound effect on the
thrombotic potential of vascular injury and stent-induced
flow disturbance. Together, these results support a critical
role for heparanase in controlling in-stent thrombosis.
Methods
Photochemical injury in genetically modified mice. All
studies were approved by the Massachusetts Institute of
Technology committee on animal care and conform to the
Guide for the Care and Use of Laboratory Animals pub-
lished by the National Institutes of Health. Transgenic mice
overexpressing heparanase were derived from those de-
scribed previously (12). The mice are transgenic for human
heparanase under the control of the constitutively active
chicken beta-actin promoter, and overexpress heparanase in
all tissues. Mice were anaesthetized with a ketamine-
xylazine mixture and a Rose Bengal dye solution (10 mg/ml)
was injected retro-orbitally into mice at a dosage of 50
mg/kg. An incision was made in the throat of the mouse
and the carotid artery of the mouse was then exposed by
careful dissection. Animals were randomly assigned to
receive no further intervention, 2 forms of local vascular
injury (mild and severe), and heparin infusion with the
latter. In some instances, the artery was subjected to mild
injury in which the forceps were used to lightly compress the
artery along its entire length, then 3 passes over the artery
Abbreviations
and Acronyms
3-OST  heparan sulfate
3-O-sulfotransferase
GP  glycoprotein
HPA Tg  heparanase
transgenic
TF  tissue factor
vWF  von Willebrand
factor
WT  wild typewere made in which a cotton tip was used to gentlycompress the artery over the forceps. In other samples, the
artery was subjected to heavy injury, which used the tech-
niques of light injury with increased force of compression
and the additional injury of compressing the artery with
forceps across the entire length. After extravascular injury, a
flow probe (Transonic, Inc., Ithaca, New York) was placed
around the artery and a 2.0-mW laser with a wavelength of
543 nm (ThorLabs Inc., Newton, New Jersey) was applied
to the artery. Blood flow was monitored until an occlusive
thrombus was formed that stopped flow for at least 2 min.
Histological characterization of injury. The carotid artery
was exposed in the mice, treated with injury, and then the aorta
was cannulated and the mouse perfused with 4 ml of saline
with heparin. The mice were then perfused with a 2%
glutaraldehyde solution. The carotid was tied with a suture at
the proximal end, excised, and stored in 2% glutaraldehyde
overnight. The vessels were then cryoprotected with progres-
sive infiltration of sucrose solutions (final concentration of 30%
sucrose), embedded in optimal cutting temperature compound,
and cryosectioned. Cryosections were cut and standard meth-
ods were used to stain hematoxylin and eosin or an elastin
Verhoeff–van Giesen stain (Electron Microscopy Sciences,
Hatfield, Pennsylvania).
Flow loop model of stent thrombosis. Mice were anesthe-
tized and blood was collected through a 20-gauge needle
inserted into the left ventricle. The collected blood was
anticoagulated using a 10% acid citrate dextrose solution
(composed of 85 mmol/l trisodium citrate, 69 mmol/l citric
acid, and 111 mmol/l glucose; pH 4.6). The anticoagulated
blood was then pooled into wild type (WT) and heparanase
transgenic (HPA Tg) groups. The thrombosis model used in
this study is a modified Chandler loop that has been described
previously (13). It employs pulsatile flow profiles with Reyn-
olds and Wormsely numbers matched to physiological condi-
tions. The loops are composed of silicon tubing (3.2 mm inside
diameter/4.8 mm outside diameter), with a reactive portion
that was coated with collagen and stented using NIR Elite
stents (9 mm  3 mm; Boston Scientific, Inc., Natick,
Massachusetts). In some cases, a mouse aorta was stented into
the reactive section of the artery. Blood from mice was injected
into flow loops using a 21-gauge needle and the flow was
maintained for 10 min. Blood was then collected in ethylene-
diamine tetraacetic acid containing collection vials and the
reactive portion of the flow loop was flushed with Tyrode
solution to remove nonadherent clot and cellular debris.
Stented segments were stored in 10% neutral buffered formalin
until further analysis.
To analyze the thrombogenicity of flow loop samples,
photographs of the segments were first taken of each
segment followed by a measurement of optical density.
Optical density measurements were performed on the re-
maining nonaorta samples (n  6) to determine the red
fibrin content of the clot. The samples were placed in a
cuvette and absorbance was measured at 405 nm. Back-
ground signal from the silicone tubing was subtracted from
all measurements. The samples were then incubated with
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April 24, 2012:1551–60 Heparanase in Stent Thrombosis0.5% uranyl acetate for 30 min, washed 3 times in deionized
water, and visualized with an environmental scanning elec-
tron microscope (Philips/FEI XL30 FEG-SEM, Hillsboro,
Oregon) in backscattering mode.
Mathematical modeling of flow over stent. Computa-
tional modeling of flow over the stent was performed as
described in the Online Appendix.
Statistical analysis. All results are shown as mean  SE of
he mean. Comparisons between only 2 groups were per-
ormed using a 2-tailed Student t test. Differences were
onsidered significant at p  0.05. Multiple comparisons
etween groups were analyzed by 2-way analysis of variance
ollowed by a Tukey post hoc test. A 2-tailed probability
alue 0.05 was considered statistically significant.
esults
eparanase overexpression increases thrombosis follow-
ng vascular injury and is neutralized with heparin treat-
ent. Vascular injury is a potent stimulus for thrombus
ormation and a potential design limitation of endovascular
tents. We used a photochemical injury model in combina-
ion with extravascular injury to understand the role of
eparanase in controlling thrombosis in response to vascular
njury. In this model, the animals were given rose bengal dye
nd a laser was applied to the carotid artery (Fig. 1A). The
B Uninjured L
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A 
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Figure 1 Photochemical Thrombosis Model Experimental Setup
(A) Experimental setup for photochemical injury model. (B) Histological staining o
Scale bar  50 m. H&E  hematoxylin and eosin stain.aser activated the dye causing oxidative damage to the endo-
helium and eventually leading to thrombosis. The time to
hrombosis was used as a measurement of the thrombogenicity
f the artery. To quantify the effects of crush injury on arterial
orphology, we injured the carotid arteries of mice and
xamined them histologically. This analysis demonstrated a
inimal effect of injury with the light injury protocol but
emonstrated stretch injury of the elastic laminae with the
eavy injury protocol (Fig. 1B). Neither protocol led to fracture
f the elastic laminae as evidenced with elastin Verhoeff–van
iesen staining. In uninjured arteries, the time to thrombosis
as similar for both WT and HPA Tg mice (Fig. 2A). With
ild injury, there was an approximately 40% decrease in time
o thrombosis (Fig. 2B). With more severe injury, there was
imilar decrease in the time-to-thrombus formation (Fig. 2C).
his effect was neutralized by the pre-treatment of the mice
ith heparin prior to heavy injury and photochemically in-
uced thrombosis (Figs. 2C and 2D). As a control for these
tudies, we examined the effects of anesthesia and extravascular
njury on levels of heparanase expression (Online Fig. 1). We
erformed detailed histological analysis on the in situ thrombi
Online Fig. 2). The thrombi formed in the flow loop
ppeared to be principally fibrin-based with increased
latelets in the heparanase overexpressing animals. The
n situ thrombi appeared to be more platelet-based.
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shear stress regions near stent struts and recirculation
zones near stent strut intersections. Stenting induces a
complex flow disturbance within the artery. Stent-induced
flow profiles are complex and can be highly thrombogenic
(14). We used a computational model to characterize the
blood flow within our ex vivo flow system. In these
simulations, we created a 3-dimensional computational
model of the NIR Elite stent geometry and simulated the
flow over 1 pulsatile cycle of flow. The wall shear stress
around the stent is shown in Figure 3A. Regions of low wall
hear stress are locations that may be of higher risk for
hrombosis. Of particular interest were regions in which there
as flow reversal and complex recirculation zones (15). These
zones of recirculation were found in regions where the stent
struts intersected (Fig. 3A). Examining the results of the
circulation analysis demonstrated recirculation zones both
upstream and downstream of the stent struts (Fig. 3A). Two
lines were drawn longitudinally through the stent and the
shear stress plotted along these lines representing the
average shear stress profiles along the stent at the top
(Fig. 3B) and bottom (Fig. 3C) of the upper panels of
Figure 3A. An analogous model for the 2-dimensional flow
over a single stent strut demonstrated a significantly larger
recirculation zone downstream from the strut (Fig. 3D).
Heparanase overexpression increases thrombosis around
stents and in stented arterial segments. To examine the
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Figure 2 Heparanase Overexpression Leads to Increased Throm
(A) Time to occlusion for uninjured arteries was similar in both wild type (WT) (n 
mice occurred faster than in WT in the presence of mild injury (n  5). *p  0.05
mice subjected to heavy arterial injury (n  4 to 6). (D) A representative flow traceeffects of heparanase overexpression on the formation ofthrombus in response to stent-induced flow disturbance, we
applied blood flow to stents in an ex vivo pulsatile flow system.
The system allows the passage of blood over stent and has been
validated as having a physiological flow profile (13). We first
flowed blood from WT or HPA Tg mice over bare-metal
stents ex vivo. After 10 min of pulsatile flow, we examined the
stents macroscopically and found visible thrombus formation
on stents treated with HPA Tg blood but not on stents treated
with WT blood (Fig. 4A). We measured the absorbance of
light at a wavelength of 405 nm as a measure of fibrin
deposition and found it was increased by nearly 3-fold with
HPA Tg versus WT blood (Fig. 4B). Stents without arterial
segments were stained and examined using environmental
scanning electron microscopy for the formation of microscopic
thrombi. HPA Tg blood formed increased thrombosis after 10
min of flow, leading to a 3-fold increase in fibrin coverage of
the stents and a dramatic increase in interstrut fibrin content
(Figs. 5A and 5B). Maximal thrombus formation occurred in
regions predicted to have disturbed flow by our computa-
tional model. A comparison of the mathematical model of
the recirculation zone found a similar distribution of fibrin
deposition with regions of recirculating flow (Fig. 5A).
Thrombosis in vascular injury is ultimately controlled by
the inherent thrombogenic potential of blood components and
the thrombogenicity of the injured arterial wall. In conven-
tional models of thrombosis, it is difficult to examine the effects
of blood versus those of the arterial wall. To address this issue,
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The tube is then mounted into an ex vivo system allowing
blood to be passed over the arterial segment and stent. We
performed this assay on WT and HPA Tg animals, including
an analysis of HPA Tg blood flowing over stented WT arterial
segments and vice versa (Figs. 6A and 6B). This analysis
evealed fairly minimal thrombus formation in WT blood–
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Figure 3 Computational Model of the Blood Flow and Wall She
(A) For the shear stress plots, the gradient of colors represents varying levels of a
(B, C) Plot of the wall shear stress on a longitudinal line passing through the sten
through a stent strut positioned against the arterial wall. This plot demonstrates t
this simulation proceeds from left to right in the diagram. Legend represents flowreated stents implanted in either HPA Tg or WT aortas buta dramatic increase in thrombosis with HPA Tg blood. The
combination of HPA Tg blood and aorta was found to have
the most thrombosis. A similar analysis was performed on
stented arterial subsegments. Interestingly, the thrombus for-
mation occurred in samples with HPA Tg blood and either
WT or HPA Tg aorta. These results indicated that heparanase
expression in the blood had a more profound effect on the
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The Virchow triad of risk factors for thrombosis includes
hypercoagulability of the blood, alterations in hemodynam-
ics, and endothelial/vessel wall injury. Endovascular inter-
ventions can induce each of these factors, and thrombosis is
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Figure 4 Heparanase Overexpression Increases the Thrombo
(A) Photographs of the stented tubes and arterial subsegments after 10 min of pu
out aortae demonstrates significantly more clot burden on HPA Tg samples (n  3
Tg mice (n  4) and blood was flowed over the stented aortic segments within theagain emerging as a critical rate-limiting factor in stent-based therapy. Whatever endothelium may be resident in
diseased vessels is rapidly lost with the placement of endovas-
cular devices (16), with accompanying arterial stretch and
deeper vascular injury forms as well. The plastic deformation of
the vessel and protrusion of the resident devices into the flow
HPA Tg
*
HPA Tg Blood 
HPA Tg Blood 
otential of Stents in an Ex Vivo Flow System
flow (n  3). (B) Optical density of the clots formed on stents implanted with-
In the other samples, stents were implanted in the aorta of WT (n  6) and HPA
o flow system. *p  0.05 versus WT samples. Abbreviations as in Figure 2.T
tic P
lsatile
). (C)
ex vivstream creates alterations in the local hemodynamics (17,18).
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even modest alterations of systemic hypercoagulability in con-
cert with these other local factors to stimulate thrombosis. We
also extend emerging data on the complex enzymatic, physio-
logic regulation of heparan sulfate biochemistry in vascular
biology. Previous studies have supported that heparan sulfate
proteoglycans can inhibit thrombosis in response to deep
vascular injury (19). In this study, we have demonstrated that
heparanase enhances the thrombotic potential of the injured
artery and thrombosis in response to the flow disturbances
caused by endovascular stents.
Previous studies have demonstrated that heparanase over-
expression induces increased levels of tissue factor (TF)
through a p38-dependent signaling pathway (20). In paral-
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Figure 5 Heparanase Overexpression Increases Thrombus Form
(A) Environmental scanning electron microscopy micrographs of stents reveal incr
observed in areas of flow reversal predicted by a computational model. Bar  100
stent struts demonstrated markedly increased thrombosis in the HPA Tg group. *plel, heparanase also appears to stimulate TF pathway inhib-itor (21). Additionally, exogenously applied heparanase has
been shown to modify in vitro coagulation on endothelial
cells in culture (20,22). Mice overexpressing heparanase also
have a mildly shortened activated partial thromboplastin
time (22). Previous studies have found that heparanase
could neutralize the anticoagulant activity of unfractionated
heparin activity (23). However, enzymatically inactive hepa-
ranase (proenzyme) did not have an effect on heparanase-
activated partial pro-thrombin time or platelet aggregation.
Recent reports have also suggested that heparanase may act
through alteration of TF and activated factor X (24,25).
Together these results suggest that heparanase has only a
moderate effect on the hypercoagulability of the blood
(overexpression of TF with compensation by TF pathway
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Heparanase in Stent Thrombosis April 24, 2012:1551–60as there was no difference between the clotting times of WT
and HPA Tg mice in the absence of vascular injury.
In stents implanted in silicone tubing, we found that
blood from heparanase overexpressing mice had a nearly
3-fold increase in thrombin deposition. This would imply
that in response to the altered hemodynamic environment
provided by the stents, heparanase overexpression increases
thrombus formation. Notably, the decrease in time to
thrombus formation was neutralized by the pre-treatment of
mice with heparin. This is primarily attributed to the
antithrombotic effect of heparin and possibly also to its
potent heparanase-inhibiting activity (26). In areas of high
shear rates, clot formation on implanted devices and the
subendothelium is highly dependent on the von Willebrand
factor (vWF) (27). Two platelet receptors bind to vWF
including glycoprotein (GP) Ib and GP IIb/IIIa (28,29).
Both are essential for the thrombus formation under high
shear rates with GP Ib mediating initial platelet adhesion
and GP IIb/IIIa binding after platelet activation (30).
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(A) Environmental scanning electron microscopy reveals increased adherence of b
titative analysis of cellular adhesion and clot formation in the stented arterial segm
samples. Abbreviations as in Figure 2.Heparin binds vWF and blocks the interaction with GP Ib(31). Thus, loss of endogenous heparan sulfate could in-
crease vWF-GP Ib interactions, facilitating clot formation
around and in the flow surrounding stent struts. Factor VIII
binds to vWF in a noncovalent association and this complex
can be internalized by cells and degraded through low-density
lipoprotein receptor-related protein in a heparan sulfate–
dependent manner (32). Heparanase has been shown to increase
the shedding of the cell surface heparan sulfate proteoglycan
syndecan-1 (33,34). Thus, shedding of cell surface heparan sulfate
proteoglycans due to heparanase excess and alterations in factor
VIII degradation may also contribute to the increased thrombosis
observed in our studies.
To examine the relative effects of heparanase overexpres-
sion on the wall and blood components separately, we
implanted stents in aortae enclosed in silicone tubing and
applied blood flow. The results demonstrated that the
combination of blood and aorta from mice overexpressing
heparanase led to the greatest extent of stent thrombosis. If
the heparanase overexpressing blood was applied to a stent
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the WT aorta or heparanase overexpressing aorta, the
thrombosis formation was greatly reduced. These results
suggest that heparanase overexpression in the blood has a
powerful effect on the thrombotic potential of implanted
endovascular stents. This potential can be reduced if there is
normal heparanase expression in the vessel and is even more
reduced if normal levels of heparanase expression are main-
tained in the blood. Clinically, heparanase levels are in-
creased in the plasma of cancer patients by 2- to 5-fold
depending on the severity and treatment of the cancer (35).
In addition, heparanase is elevated in patients with diabetes,
renal diseases, colitis, rheumatoid arthritis, and atheroscle-
rotic lesions (11,36,37). Platelets contain large amounts of
heparanase in their  granules, yet its function has not been
elucidated. Clearly, activated platelets provide a major
source for plasma heparanase, as do neutrophils and other
cells of immune system (38), and activated vascular endo-
thelial cells (9). Notably, large amounts of heparanase are
found in wound fluid (39) and the synovial fluid of rheu-
matoid arthritis patients (36). We have recently demon-
strated that heparanase expression is augmented in the
neointima formed after stent implantation in diabetic ani-
mals and that heparanase regulates the formation of neoin-
timal hyperplasia following vascular injury (7). Both patients
with diabetes and end-stage renal disease have increased risk
of stent thrombosis (40), and our results suggest that
heparanase expression may be a contributing factor to this
clinical finding.
In the absence of vascular injury, we found no difference
in the clotting times in the laser-induced injury model in
heparanase overexpressing mice. The laser-induced injury
model causes oxidative damage to the endothelium leading to
thrombosis (41). This model produces endothelial injury in the
absence of altered hemodynamics and hypercoagulability. In
this context, our studies support the theory that, in terms of
baseline endothelial injury or dysfunction, overexpression of
heparanase has little effect on thrombosis. Endogenous hepa-
ran sulfate has been widely considered to have anticoagula-
tory properties (42); however, some studies have questioned
the role of heparan sulfate in normal hemostasis (43). Our
findings are consistent with previous studies that examined
the role of heparan sulfate 3-O-sulfotransferase-1 (3-
OST-1) on thrombosis in mice (44). Three-OST-1 is the
rate-limiting enzyme for the formation of antithrombin
binding motifs in heparan sulfate. Knockout of 3-OST-1 in
mice leads to the loss of the majority of anticoagulant
heparan sulfate but did not alter thrombosis time in a
FeCl3-induced thrombosis model (44). Heparanase overex-
pressing mice demonstrate increased heparan sulfate degra-
dation (12). In particular, heparanase can cut the antithrom-
bin binding motif within heparan sulfate (45). Thus, the
results on 3-OST-1 and our results are consistent with the
notion that in a vessel with simple endothelial injury,
heparan sulfate does not play a critical role in preventing
thrombosis.Taken together, our results demonstrate that heparanase
has a profound impact on the thrombotic response to
endovascular stenting. In context of the Virchow triad of
thrombotic risk factors, we have shown that heparanase
alters the thrombotic potential of flow-induced changes and
the inherent hypercoagulability of the blood during vascular
injury, but that it has little effect in the case of endothelial
injury without accompanying deeper arterial injury. Many
clinically relevant disorders such as diabetes and cancer can
increase both blood and tissue levels of heparanase (46–48).
linical studies have also suggested that comorbidity with
ancer is a potential risk factor for stent thrombosis (49).
ur work supports the theory that heparanase excess in both
he blood and arterial tissue work synergistically to make
ndovascular stent implantation highly thrombogenic. Con-
equently, our studies imply that heparanase inhibitors may
rovide augmentation to traditional anticoagulatory thera-
ies and reduce the risk of thrombotic events in patients
ith elevated levels of heparanase due to diabetes, cancer, or
ther diseases.
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APPENDIX
For information about the computational modeling of flow over the stent,
please see the online version of this paper.
